Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Adefovir Dipivoxil

FDA-approved product (tablet, oral), marketed as Adefovir Dipivoxil, Hepsera.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Adefovir Dipivoxil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis B virus infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF08

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Adefovir Dipivoxil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Adefovir Dipivoxil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Extension Study of Carvedilol RCT Study

    NCT05021406 · start 2021-01-08

    Registered record
    Registry ID
    NCT05021406
    Conditions
    Liver Cirrhosis; Portal Hypertension
    Interventions
    Carvedilol 12.5 MG
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-01-08
    Completion
    2024-10-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis; Portal Hypertension
    InterventionCarvedilol 12.5 MG
    PhaseNot applicable
    Registry statusUnknown

  • Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients

    NCT04724785 · start 2020-12-01

    Registered record
    Registry ID
    NCT04724785
    Conditions
    Sustained Virologic Response; Hepatitis B, Chronic
    Interventions
    only monitoring; monitoring and regimen change if necessary; regimen change
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-12-01
    Completion
    2022-12-31
    Enrolment
    10,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSustained Virologic Response; Hepatitis B, Chronic
    Interventiononly monitoring; monitoring and regimen change if necessary; regimen change
    PhaseNot recorded
    Registry statusUnknown

  • Carvedilol for Prevention of Esophageal Varices Progression

    NCT03736265 · start 2017-10-09

    Registered record
    Registry ID
    NCT03736265
    Conditions
    Cirrhosis, Liver; Portal Hypertension
    Interventions
    Carvedilol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-10-09
    Completion
    2022-12-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis, Liver; Portal Hypertension
    InterventionCarvedilol
    PhaseNot applicable
    Registry statusUnknown

  • Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy

    NCT03366571 · start 2016-01

    Registered record
    Registry ID
    NCT03366571
    Conditions
    Chronic Hepatitis B
    Interventions
    Nucleos(t)ide Analogues
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2016-01
    Completion
    2024-12
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionNucleos(t)ide Analogues
    PhaseNot recorded
    Registry statusUnknown

  • An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients

    NCT02560649 · start 2015-05

    Registered record
    Registry ID
    NCT02560649
    Conditions
    Chronic Hepatitis B
    Interventions
    Peginterferon alfa-2a plus Entecavir; Peginterferon alfa-2a plus Lamivudine; Peginterferon alfa-2a plus Adefovir; Peginterferon alfa-2a plus Tenofovir; Entecavir; Lamivudine; Adefovir; Tenofovir disoproxil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-05
    Completion
    2017-02
    Enrolment
    324

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionPeginterferon alfa-2a plus Entecavir; Peginterferon alfa-2a plus Lamivudine; Peginterferon alfa-2a plus Adefovir; Peginterferon alfa-2a plus Tenofovir +4 more
    PhasePhase 4
    Registry statusUnknown

  • A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)

    NCT02327416 · start 2014-10

    Registered record
    Registry ID
    NCT02327416
    Conditions
    Hepatitis B, Chronic
    Interventions
    Y peginterferon alfa-2b; Granulocyte-macrophage colony stimulating factor; Entecavir and or adefovir dipivoxil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-10
    Completion
    2019-06
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionY peginterferon alfa-2b; Granulocyte-macrophage colony stimulating factor; Entecavir and or adefovir dipivoxil
    PhasePhase 3
    Registry statusUnknown

  • The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B

    NCT02965859 · start 2012-12

    Registered record
    Registry ID
    NCT02965859
    Conditions
    Chronic Hepatitis B
    Interventions
    Metacavir Enteric-coated Capsules 80mg; Metacavir Enteric-coated Capsules 160mg; Metacavir Enteric-coated Capsules 320mg; Metacavir Enteric-coated Capsules Placebo 240mg; Metacavir Enteric-coated Capsules Placebo 160mg; Metacavir Enteric-coated Capsules Placebo 320mg; Adefovir Dipivoxil Capsule10mg; Adefovir Dipivoxil Capsule Placebo 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2012-12
    Completion
    Not recorded
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionMetacavir Enteric-coated Capsules 80mg; Metacavir Enteric-coated Capsules 160mg; Metacavir Enteric-coated Capsules 320mg; Metacavir Enteric-coated Capsules Placebo 240mg +4 more
    PhasePhase 2
    Registry statusUnknown

  • Difference in Efficacy Between Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients

    NCT01718587 · start 2012-11

    Registered record
    Registry ID
    NCT01718587
    Conditions
    Liver Cirrhosis
    Interventions
    stem cell transplantation through interventional procedure; antiviral therapy (lamivudine, other antiviral drugs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2012-11
    Completion
    2014-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis
    Interventionstem cell transplantation through interventional procedure; antiviral therapy (lamivudine, other antiviral drugs)
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Antiviral Efficacy of Switching to ETV Plus TDF

    NCT01597934 · start 2012-08

    Registered record
    Registry ID
    NCT01597934
    Conditions
    Chronic Hepatitis B
    Interventions
    Group A (Zeffix, Sebivo, Hepsera); Group B (Baraclude, Viread)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-08
    Completion
    2014-05
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionGroup A (Zeffix, Sebivo, Hepsera); Group B (Baraclude, Viread)
    PhasePhase 4
    Registry statusUnknown

  • PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients

    NCT01373684 · start 2012-05-25

    Registered record
    Registry ID
    NCT01373684
    Conditions
    Chronic Hepatitis B
    Interventions
    Peginterferon alfa-2a; Nucleos(t)ide analogue
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-05-25
    Completion
    2019-10-28
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionPeginterferon alfa-2a; Nucleos(t)ide analogue
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study

    NCT01804387 · start 2011-05

    Registered record
    Registry ID
    NCT01804387
    Conditions
    Chronic Hepatitis B
    Interventions
    telbivudine plus adefovir; lamivudine plus adefovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-05
    Completion
    2014-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    Interventiontelbivudine plus adefovir; lamivudine plus adefovir
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)

    NCT01300234 · start 2011-03-30

    Registered record
    Registry ID
    NCT01300234
    Conditions
    Hepatitis B
    Interventions
    Tenofovir disoproxil fumarate (TDF) tablets; Adefovir dipivoxil (ADV) tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03-30
    Completion
    2016-12-06
    Enrolment
    512

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    InterventionTenofovir disoproxil fumarate (TDF) tablets; Adefovir dipivoxil (ADV) tablets
    PhasePhase 3
    Registry statusCompleted

  • Lamivudine and Adefovir Dipivoxil Fixed Dose Combination

    NCT01353742 · start 2011-02-21

    Registered record
    Registry ID
    NCT01353742
    Conditions
    Hepatitis B, Chronic
    Interventions
    Lamivudine; Adefovir dipivoxil; Fixed dose combination (Lamivudine and Adefovir dipivoxil)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-02-21
    Completion
    2011-04-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionLamivudine; Adefovir dipivoxil; Fixed dose combination (Lamivudine and Adefovir dipivoxil)
    PhasePhase 1
    Registry statusCompleted

  • An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B

    NCT01264354 · start 2010-03

    Registered record
    Registry ID
    NCT01264354
    Conditions
    Chronic Hepatitis B
    Interventions
    Clevudine 30mg; Clevudine 20mg+Adefovir dipivoxil 10mg; Clevudine 20mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-03
    Completion
    2013-02
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionClevudine 30mg; Clevudine 20mg+Adefovir dipivoxil 10mg; Clevudine 20mg
    PhasePhase 4
    Registry statusCompleted

  • Entecavir Plus Adefovir in Lamivudine-Resistant Patients

    NCT00986778 · start 2009-12

    Registered record
    Registry ID
    NCT00986778
    Conditions
    Hepatitis B, Chronic
    Interventions
    Lamivudine; Entecavir; Adefovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2009-12
    Completion
    2014-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionLamivudine; Entecavir; Adefovir
    PhasePhase 4
    Registry statusWithdrawn